Chronological Changes in Neutrophil/lymphocyte Ratio in Advanced Gastric Cancer Patients Treated with Nivolumab: a Report of Nine Cases.
Gastric cancer
neutrophil/lymphocyte ratio
nivolumab
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Oct 2020
01 Oct 2020
Historique:
received:
19
03
2020
entrez:
28
10
2020
pubmed:
29
10
2020
medline:
25
6
2021
Statut:
epublish
Résumé
Nivolumab has been approved for use in advanced gastric cancer (GC) after third-line chemotherapy in Japan. However, it remains difficult to predict favorable nivolumab response before treatment. We evaluated the clinical course with a focus on the chronological changes in neutrophil/lymphocyte ratio (NLR) throughout the chemotherapy and assessed the relationship between nivolumab response and chronological changes in NLR before nivolumab administration. We experienced nine cases who received nivolumab monotherapy for unresectable advanced or postoperative recurrent GC. Nivolumab was used as third-line chemotherapy in all patients, and partial response (PR) and stable disease (SD) were observed in two patients each. Nivolumab treatment resulted in progressive disease (PD) in five patients. In patients with PR or SD, changes in the NLR tended to correspond to the response of target metastatic lymph nodes to first- and second-line chemotherapy. In the four cases with PR or SD following nivolumab, ∆NLRresponses that was the difference in the degree of decline during the most effective pretreatment chemotherapy were 1.39, 0.73, 1.62, and 1.22. However, the patients with PD showed lower ∆NLRresponses, at 0.66, 0.66, 0.25, 0.13, and -0.05 in the five cases. Mean ∆NLRresponses in the patients with PR or SD and patients with PD were 1.17 and 0.33, respectively (P = 0.0008). We experienced nine GC cases treated with nivolumab and assessed the association between chronological NLR changes throughout chemotherapy and tumor response to nivolumab. Changes in NLR during pretreatment chemotherapy might predict tumor response to nivolumab monotherapy in patients with advanced GC.<br />.
Sections du résumé
BACKGROUND
BACKGROUND
Nivolumab has been approved for use in advanced gastric cancer (GC) after third-line chemotherapy in Japan. However, it remains difficult to predict favorable nivolumab response before treatment.
METHODS
METHODS
We evaluated the clinical course with a focus on the chronological changes in neutrophil/lymphocyte ratio (NLR) throughout the chemotherapy and assessed the relationship between nivolumab response and chronological changes in NLR before nivolumab administration.
RESULTS
RESULTS
We experienced nine cases who received nivolumab monotherapy for unresectable advanced or postoperative recurrent GC. Nivolumab was used as third-line chemotherapy in all patients, and partial response (PR) and stable disease (SD) were observed in two patients each. Nivolumab treatment resulted in progressive disease (PD) in five patients. In patients with PR or SD, changes in the NLR tended to correspond to the response of target metastatic lymph nodes to first- and second-line chemotherapy. In the four cases with PR or SD following nivolumab, ∆NLRresponses that was the difference in the degree of decline during the most effective pretreatment chemotherapy were 1.39, 0.73, 1.62, and 1.22. However, the patients with PD showed lower ∆NLRresponses, at 0.66, 0.66, 0.25, 0.13, and -0.05 in the five cases. Mean ∆NLRresponses in the patients with PR or SD and patients with PD were 1.17 and 0.33, respectively (P = 0.0008).
CONCLUSIONS
CONCLUSIONS
We experienced nine GC cases treated with nivolumab and assessed the association between chronological NLR changes throughout chemotherapy and tumor response to nivolumab. Changes in NLR during pretreatment chemotherapy might predict tumor response to nivolumab monotherapy in patients with advanced GC.<br />.
Identifiants
pubmed: 33112554
doi: 10.31557/APJCP.2020.21.10.2955
pmc: PMC7798180
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2955-2960Références
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Lancet Oncol. 2018 Nov;19(11):1437-1448
pubmed: 30355453
Bratisl Lek Listy. 2001;102(1):5-14
pubmed: 11723675
Gastric Cancer. 2010 Aug;13(3):170-6
pubmed: 20820986
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
Surg Case Rep. 2018 Jul 5;4(1):71
pubmed: 29978335
Front Oncol. 2019 Dec 16;9:1375
pubmed: 31921639
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Onco Targets Ther. 2018 Nov 21;11:8239-8250
pubmed: 30538493
J Immunol. 1987 Oct 1;139(7):2406-13
pubmed: 2821114
Cancer Med. 2018 Jun;7(6):2612-2620
pubmed: 29673110
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
World J Surg Oncol. 2019 Jun 25;17(1):108
pubmed: 31238937
Gan To Kagaku Ryoho. 2016 Jun;43(6):678-82
pubmed: 27306805
Anticancer Res. 2011 Sep;31(9):2995-8
pubmed: 21868550
J Immunol. 1985 Jan;134(1):230-4
pubmed: 3871101
Front Oncol. 2020 Feb 17;10:130
pubmed: 32128313
Clin J Gastroenterol. 2019 Feb;12(1):15-19
pubmed: 30206777
Cancer Chemother Pharmacol. 2020 Feb;85(2):265-272
pubmed: 31907646
In Vivo. 2020 Mar-Apr;34(2):583-585
pubmed: 32111756
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Oncotarget. 2018 Oct 2;9(77):34520-34527
pubmed: 30349646
J Surg Oncol. 2005 Sep 1;91(3):181-4
pubmed: 16118772
Br J Cancer. 2020 May;122(10):1507-1517
pubmed: 32203221